• 5th Floor. Amrita Tower, KPCC Junction, MG Road Kochi

About Us

WHO WE ARE

PNB Vesper Life Sciences Pvt. Ltd

PNB Vesper Life Sciences Pvt. Ltd is a research-based bio-pharmaceutical organization that is determined to discover drugs for serious diseases and unmet medical conditions. PNB Vesper is currently one of very few companies in India that is focused only on research-based NCEs, rather than generics.

The company based in Kochi, India was incorporated in the year 2011. The company’s promoters have been contracting its preclinical research and development activities with various reputed academic and commercial organizations in UK, US, Thailand, and India for the last 14 years (even before incorporating PNB Vesper Life Science in 2011).PNB Vesper’s products arise from five programs, cholecystokinin receptor (CCK) program that were under development for more than a decade.

PNB Vesper is actually ivolved in developing drugs for unmet medical needs.. PNB Vesper has synthezised hundreds of molecules and systematically characterized to select lead molecules. The lead molecules have the potential to treat variety of diseases including pain, cancer, inflammation such as inflammatory bowel disease (IBD), neurological diseases such as anxiety, depression, metabolic diseases, and others. PNB Vesper’s assets are well protected by intellectual property filings both in US and many other countries in the around the World, which will not expire until 2036.

The Company currently has 5 molecules under development, 3 (New Chemical Entities) NCE in preclinical phases, 2 molecules in clinical phases.

  • PNB 001/ GPP-BALACOVIN – CCK2 gastrin antagonist, for the treatment of inflammatory pain and inflammatory bowel disease (IBD), Dysmenorrhea and COVID 19.
  • PNB 028- CCK3a or CCK-C isoform-selective antagonist, developed for the treatment of colon and pancreatic cancer.
  • PNB 081- CCK1 or CCK-A antagonist for the treatment of pancreatitis and opiate management
  • PNB 101- CCK3b or CCK C gastrin isoform selective irreversible antagonist, developed for the treatment of Gastric Cancer and Lung Cancer.
  • PNB 291- A pan CCK antagonist, is in late discovery stage for the treatment of CCK + gastrin cancers such as lung, liver and
    brain cancer.

PNB Vesper is currently functioning as a semi-virtual organization with most of its clinical research, preclinical research, and development activities being conducted by various reputed academic and commercial organizations in the UK, US, Thailand, and India. PNB Vesper’s assets are well protected by intellectual property filings both in the US and many other countries around the World, which will not expire until 2036.